【摘要】 目的观察环磷腺苷葡胺联合单硝酸异山梨酯(欣康)治疗慢性肺心病急性加重期临床疗效。方法80例慢性肺心病急性加重期病人,随机分为观察组与对照组两组,每组40例。对照组在常规治疗的基础上,适量应用西地兰治疗;观察组采用环磷腺苷葡胺联合欣康治疗,10d后观察疗效。结果观察组治疗前后动脉血氧分压、动脉血二氧化碳分压、1s用力呼气量占用力肺活量比值、最大呼气中段流量、三尖瓣最大反流速度及收缩期肺动脉压差值与对照组比较,差异均有显著性(t=2.98～12.97,P<0.05)。观察组疗效明显优于对照组,差异有显著性(uc=3.41,P<0.05)。结论环磷腺苷葡胺联合欣康治疗慢性肺心病急性加重期疗效较好。更多还原

【Abstract】 Objective To observe clinical efficacy of combined meglumine adenosine cyclophosphate with isosorbide mononitrate(Xinkang) in the treatment of chronic cardiopulmonary heart disease(CPHD) in acute exacerbation(AE) stage.Methods Eighty CPHD patients in AE stage were equally randomized to observation group(combined therapy group) and control group.The patients in the control group received appropriate amount of cedilanid in addition to conventional therapy,those in the observation were offered combined therapy.The efficacy in the two groups was assessed after 10 days.Results After the treatment,PaO2,PaCO2,FEV1.0%,MMEF,three-tricuspid maximum velocity of reflux and pulmonary arterial pressure in the observation group were significant difference than those in the control group(t=2.98-12.97,P<0.05).The efficacy in the observation group was much better than that in the control,the difference being significant(uc=3.41,P<0.05).Conclusion The therapeutic effect is good by applying combined meglumine adenosine cyclophosphate with Xinkang for chronic cardiopulmonary di-sease in acute exacerbation stage.更多还原